Arrayit Corp. $ARYC News Last updated 12/26/2016
Post# of 273249
Posted On: 12/26/2016 5:27:14 AM
Arrayit Corp. $ARYC News
Last updated 12/26/2016 - 0.0002
DUE DILIGENCE REPORT: Arrayit Corp. Shares a Bargain Now - Small Cap Street
Sep 28, 2015
Service
-
DUE DILIGENCE REPORT: Arrayit Corp. Shares a Bargain Now - Small Cap Street
PR Newswire
NEW YORK, Sept. 28, 2015
NEW YORK, Sept. 28, 2015 /PRNewswire/ -- Small Cap Street issues due diligence report. Arrayit Corp. (OTCQB: ARYC) shares closed at $.0035 in Friday's session, up 9.38%. Trading volume was less than average at 4.2 million shares.
Our due diligence will show investors in Arrayit Corp the information they need. Get our report at the link below.
http://bit.ly/-ARYC_Due_Diligence
Copy and paste to browser may be required.
About Arrayit Corporation
Arrayit leads professionals in the microarray industry by developing, manufacturing and marketing life science tools and integrated laboratory platforms for the analysis of genetic variation, biological function, and diagnostics. Arrayit provides it specialized equipment, tools, microarray manufacturing services to more than 10,000 research laboratories, pharmaceutical companies, academic institutions, clinical research organizations, government agencies and biotechnology companies around the globe.
About Small Cap Street
We make the connection between sophisticated investors and high quality public companies. An issuer of reports written by financial analysts who provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.
Safe Harbor Statement
This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research provider. However, we are only human and may make mistakes. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and coinciding reports. For more information and services provided beyond this press release please use contact information provided below. If you notice any errors or omissions, please notify us.
Contact: editor@smallcapstreet.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/due-diligence-report-arrayit-corp-shares-a-bargain-now--small-cap-street-300149719.html
SOURCE Small Cap Street
Copyright © 2015 PR Newswire. All Rights Reserved
Small Cap IR - Empowering the Age of Genetic Enlightenment
Jun 30, 2015
Service
-
Small Cap IR - Empowering the Age of Genetic Enlightenment
PR Newswire
NEW YORK, June 30, 2015
NEW YORK, June 30, 2015 /PRNewswire/ – Small Cap IR issues report. Recently, Arrayit Corporation (OTCQB: ARYC) had an agreement to supply custom Arrayit blood card technology to Vivos' Global Genome Vault, the only private human DNA vault on earth. Vivos offers an impervious, impenetrable and permanent DNA storage vault, able to provide virtually every man, woman and child on Earth, a safe and secure nuclear blast-proof, underground shelter to store their DNA. Arrayit blood cards allow the rapid collection, separation, drying and storage of human genomic DNA in a format that is permanent and highly miniaturized.
Volume has increased dramatically since the agreement with Vivos' Global Genome Vault and price per share has yet to find a trading range. In the last five trading sessions hitting a low of $0.0035 and a high of $0.007.
To gain a better understanding of the recent events read the analyst brief. The analyst brief can be viewed in its entirety by using the link below. There is no cost obligation required to view this report.
http://bit.ly/_ARYC_AnalystReport
Copy and paste to browser may be required.
About Arrayit Corporation
Arrayit Corporation (OTCQB: ARYC) leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It offers its tools and services to genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies.
About Small Cap IR
We make the connection between sophisticated investors and high quality micro - small cap companies. We are an issuer of reports written by research analysts who provide an educated opinion of the profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges. For more information and services provided beyond this release please use contact information provided below.
FORWARD-LOOKING DISCLAIMER
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report. This document, article or report is written and authored by a 3rd party research analyst. However, we are only human and make mistakes. If you notice any errors or omissions, please notify us below.
Contact: admin@smallcapir.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/small-cap-ir---empowering-the-age-of-genetic-enlightenment-300106611.html
SOURCE Small Cap IR
Copyright © 2015 PR Newswire. All Rights Reserved
Avant Diagnostics, Inc. Begins OvaDx FDA Trials and Engages Clinical Research Organization
Apr 15, 2015
Service
-
Avant Diagnostics, Inc. (OTCBB: AVDX) (“Avant”), a diagnostic company with a primary focus on the commercialization of a proprietary diagnostic test for the early detection of ovarian cancer called OvaDx®, is pleased to announce that it has engaged the professional services of DOCRO, Inc. (“DOCRO”) to manage the preparation and the submission of the pre-submission package for OvaDx® and to conduct the negotiation with the U.S. Food and Drug Administration (“FDA”) office for the process for obtaining a 510(k) clearance of the OvaDx® device intended for use as an aid in monitoring women diagnosed with ovarian cancer. Additionally, Avant purchased the necessary ovarian cancer samples required for the supervised, double blinded clinical validation testing data to be included in the pre-submission package.
Gregg Linn, Avant’s President and Chief Executive Officer, noted, “I am thrilled finally to reach this milestone. Since I joined the company almost 2½ years ago, my goal was simply to take OvaDx® through the FDA submission process for ovarian cancer monitoring, seek FDA clearance, and most importantly, save lives.”
About Avant Diagnostics, Inc.
Avant Diagnostics, Inc. is a medical diagnostic technology company that specializes in large panel biomarker screening. Our first test, OvaDx®, developed in conjunction with Arrayit Corporation (OTCQB: ARYC), detects for pre-symptomatic ovarian cancer. OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Pre-clinical research studies with OvaDx® indicated high sensitivity and specificity for all types and stages of ovarian cancer, including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA 510(k) clearance, Avant intends to sell or license OvaDx® as a diagnostic test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer.
Safe Harbor Statement
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Avant's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Avant does not undertake an obligation to update or revise any forward-looking statement except as required by law. Investors should read the risk factors set forth in Avant’s Form 8-K filed with the Securities and Exchange Commission on January 14, 2015, as amended on January 16, 2015, and other periodic reports filed with the Securities and Exchange Commission.
Copyright © 2015 Businesswire. All Rights Reserved
Arrayit Corporation Debuts Major New Genomics and Proteomics Products in 2015/2016 Catalog
Feb 11, 2015
Service
-
SUNNYVALE, Calif., Feb. 11, 2015 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTCQB:ARYC), a life sciences and molecular diagnostics leader, announces today that the company is debuting major new products and services for the billion dollar genomics and proteomics markets in the company's new full color, image-rich 2015/2016 catalog. Arrayit High-Seq™ genomic labeling kits, HuProt™ v2.0 19K human proteome microarrays, InnoScan® 910 and 1100 microarray scanners, series 3 glass consumables, and TissueMax™ personal tissue microarrayers featured in the new catalog are speeding basic research and clinical medicine to improve healthcare, agriculture and food safety.
Arrayit has enhanced its patented and proprietary microarray platform to accelerate the analysis of the human genome and proteome, which are the blueprints that carry out the inherited and real-time instructions of the human body and impart the function of all living organisms. Deeper genomic and proteomic information is leading to pre-symptomatic diagnostic tests, safer medicines and a personalized healthcare paradigm in which patients receive treatments based on their unique complement of genes and proteins. Arrayit's 2015/2016 catalog showcases the new products and services, which are available worldwide through direct sales and a network of 60 international distributors. Arrayit customers include university and government laboratories, life sciences and biotechnology firms and the world's largest pharmaceutical companies.
"We have made a significant R&D investment to create innovative new genomics and proteomics products for the life sciences market," states Arrayit CEO Rene Schena. "The value-added, cost-effective solutions featured in our new catalog will drive company revenues and earnings beginning in the first quarter of this year."
About Arrayit Corporation
Arrayit utilizes its patented and proprietary microarray platform to lead and empower the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.
- Powerful Science for Life™
Visit www.arrayit.com or more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2013 and in Form 10-Q for the quarterly period ended September 30, 2014.
CONTACT: Investor Relations
Arrayit Corporation
408.744.1331
investorrelations@arrayit.com
Copyright © 2015 GlobeNewswire. All Rights Reserved
Arrayit Corporation Subsidiary Avant Diagnostics, Inc. Acquired by American Liberty Petroleum Corporation
Dec 31, 2014
Service
-
SUNNYVALE, Calif., Dec. 31, 2014 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTCQB:ARYC) announces that its subsidiary Avant Diagnostics, Inc., a medical technology company developing cutting edge medical diagnostic tests, has been acquired by American Liberty Petroleum Corporation (OTCBB:OREO). The board of directors and a majority of shareholders of American Liberty Petroleum Corporation have authorized a number of corporate actions in order to complete the acquisition, including a reverse split, a name change, authorization of Preferred Stock, and filing the required SEC disclosure statements. Upon the effectiveness of these corporate actions, Gregg Linn, Avant's CFO, will join the board of directors of the company as CEO and President.
In cooperation with Arrayit Corporation and DOCRO, Avant Diagnostics, Inc. is pursuing FDA approval of the market's first large panel biomarker monitoring and screening test for ovarian cancer. OvaDx® is an advanced microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA approval, Avant Diagnostics will offer OvaDx® as an elective test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer. OvaDx® will be used by doctors to advance the forefront of ovarian cancer treatment including improved surgical options, more effective chemotherapies, and to supplement existing tests including CA-125, OVA1®, and transvaginal ultrasound.
Safe Harbor
We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2014.
CONTACT: Investor Contact
Investor Relations
Arrayit Corporation
investorrelations@arrayit.com
Gregg Linn, CFO
Avant Diagnostics, Inc.
investors@avantdiagnostics.com
Copyright © 2014 GlobeNewswire. All Rights Reserved
OTC Markets Group Welcomes Arrayit to OTCQB
Dec 03, 2014
Service
New York, NY -
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced Arrayit Corporation (OTCQB: ARYC) is verified for trading on OTCQB®, the venture marketplace for entrepreneurial and development stage companies, effective December 3, 2014.
Arrayit leads professionals in the microarray industry by developing, manufacturing and marketing life science tools and integrated laboratory platforms for the analysis of genetic variation, biological function, and diagnostics. Arrayit provides its specialized equipment, tools, microarray manufacturing services to more than 10,000 research laboratories, pharmaceutical companies, academic institutions, clinical research organizations, government agencies and biotechnology companies around the globe.
U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX:OTCM) operates Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities. Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. We organize these securities into marketplaces to better inform investors of opportunities and risks – OTCQX®, The Best Marketplace; OTCQB®, The Venture Marketplace; and OTC Pink®, The Open Marketplace. Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors. To learn more about how we create better informed and more efficient financial marketplaces, visit www.otcmarkets.com.
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed
Media Contact:
Saskia Sidenfaden, OTC Markets Group Inc., +1 (212) 896-4428, saskia@otcmarkets.com
Copyright © 2014 OTC Markets. All Rights Reserved
Last updated 12/26/2016 - 0.0002
DUE DILIGENCE REPORT: Arrayit Corp. Shares a Bargain Now - Small Cap Street
Sep 28, 2015
Service
-
DUE DILIGENCE REPORT: Arrayit Corp. Shares a Bargain Now - Small Cap Street
PR Newswire
NEW YORK, Sept. 28, 2015
NEW YORK, Sept. 28, 2015 /PRNewswire/ -- Small Cap Street issues due diligence report. Arrayit Corp. (OTCQB: ARYC) shares closed at $.0035 in Friday's session, up 9.38%. Trading volume was less than average at 4.2 million shares.
Our due diligence will show investors in Arrayit Corp the information they need. Get our report at the link below.
http://bit.ly/-ARYC_Due_Diligence
Copy and paste to browser may be required.
About Arrayit Corporation
Arrayit leads professionals in the microarray industry by developing, manufacturing and marketing life science tools and integrated laboratory platforms for the analysis of genetic variation, biological function, and diagnostics. Arrayit provides it specialized equipment, tools, microarray manufacturing services to more than 10,000 research laboratories, pharmaceutical companies, academic institutions, clinical research organizations, government agencies and biotechnology companies around the globe.
About Small Cap Street
We make the connection between sophisticated investors and high quality public companies. An issuer of reports written by financial analysts who provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.
Safe Harbor Statement
This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research provider. However, we are only human and may make mistakes. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and coinciding reports. For more information and services provided beyond this press release please use contact information provided below. If you notice any errors or omissions, please notify us.
Contact: editor@smallcapstreet.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/due-diligence-report-arrayit-corp-shares-a-bargain-now--small-cap-street-300149719.html
SOURCE Small Cap Street
Copyright © 2015 PR Newswire. All Rights Reserved
Small Cap IR - Empowering the Age of Genetic Enlightenment
Jun 30, 2015
Service
-
Small Cap IR - Empowering the Age of Genetic Enlightenment
PR Newswire
NEW YORK, June 30, 2015
NEW YORK, June 30, 2015 /PRNewswire/ – Small Cap IR issues report. Recently, Arrayit Corporation (OTCQB: ARYC) had an agreement to supply custom Arrayit blood card technology to Vivos' Global Genome Vault, the only private human DNA vault on earth. Vivos offers an impervious, impenetrable and permanent DNA storage vault, able to provide virtually every man, woman and child on Earth, a safe and secure nuclear blast-proof, underground shelter to store their DNA. Arrayit blood cards allow the rapid collection, separation, drying and storage of human genomic DNA in a format that is permanent and highly miniaturized.
Volume has increased dramatically since the agreement with Vivos' Global Genome Vault and price per share has yet to find a trading range. In the last five trading sessions hitting a low of $0.0035 and a high of $0.007.
To gain a better understanding of the recent events read the analyst brief. The analyst brief can be viewed in its entirety by using the link below. There is no cost obligation required to view this report.
http://bit.ly/_ARYC_AnalystReport
Copy and paste to browser may be required.
About Arrayit Corporation
Arrayit Corporation (OTCQB: ARYC) leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It offers its tools and services to genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies.
About Small Cap IR
We make the connection between sophisticated investors and high quality micro - small cap companies. We are an issuer of reports written by research analysts who provide an educated opinion of the profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges. For more information and services provided beyond this release please use contact information provided below.
FORWARD-LOOKING DISCLAIMER
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report. This document, article or report is written and authored by a 3rd party research analyst. However, we are only human and make mistakes. If you notice any errors or omissions, please notify us below.
Contact: admin@smallcapir.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/small-cap-ir---empowering-the-age-of-genetic-enlightenment-300106611.html
SOURCE Small Cap IR
Copyright © 2015 PR Newswire. All Rights Reserved
Avant Diagnostics, Inc. Begins OvaDx FDA Trials and Engages Clinical Research Organization
Apr 15, 2015
Service
-
Avant Diagnostics, Inc. (OTCBB: AVDX) (“Avant”), a diagnostic company with a primary focus on the commercialization of a proprietary diagnostic test for the early detection of ovarian cancer called OvaDx®, is pleased to announce that it has engaged the professional services of DOCRO, Inc. (“DOCRO”) to manage the preparation and the submission of the pre-submission package for OvaDx® and to conduct the negotiation with the U.S. Food and Drug Administration (“FDA”) office for the process for obtaining a 510(k) clearance of the OvaDx® device intended for use as an aid in monitoring women diagnosed with ovarian cancer. Additionally, Avant purchased the necessary ovarian cancer samples required for the supervised, double blinded clinical validation testing data to be included in the pre-submission package.
Gregg Linn, Avant’s President and Chief Executive Officer, noted, “I am thrilled finally to reach this milestone. Since I joined the company almost 2½ years ago, my goal was simply to take OvaDx® through the FDA submission process for ovarian cancer monitoring, seek FDA clearance, and most importantly, save lives.”
About Avant Diagnostics, Inc.
Avant Diagnostics, Inc. is a medical diagnostic technology company that specializes in large panel biomarker screening. Our first test, OvaDx®, developed in conjunction with Arrayit Corporation (OTCQB: ARYC), detects for pre-symptomatic ovarian cancer. OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Pre-clinical research studies with OvaDx® indicated high sensitivity and specificity for all types and stages of ovarian cancer, including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA 510(k) clearance, Avant intends to sell or license OvaDx® as a diagnostic test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer.
Safe Harbor Statement
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Avant's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Avant does not undertake an obligation to update or revise any forward-looking statement except as required by law. Investors should read the risk factors set forth in Avant’s Form 8-K filed with the Securities and Exchange Commission on January 14, 2015, as amended on January 16, 2015, and other periodic reports filed with the Securities and Exchange Commission.
Copyright © 2015 Businesswire. All Rights Reserved
Arrayit Corporation Debuts Major New Genomics and Proteomics Products in 2015/2016 Catalog
Feb 11, 2015
Service
-
SUNNYVALE, Calif., Feb. 11, 2015 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTCQB:ARYC), a life sciences and molecular diagnostics leader, announces today that the company is debuting major new products and services for the billion dollar genomics and proteomics markets in the company's new full color, image-rich 2015/2016 catalog. Arrayit High-Seq™ genomic labeling kits, HuProt™ v2.0 19K human proteome microarrays, InnoScan® 910 and 1100 microarray scanners, series 3 glass consumables, and TissueMax™ personal tissue microarrayers featured in the new catalog are speeding basic research and clinical medicine to improve healthcare, agriculture and food safety.
Arrayit has enhanced its patented and proprietary microarray platform to accelerate the analysis of the human genome and proteome, which are the blueprints that carry out the inherited and real-time instructions of the human body and impart the function of all living organisms. Deeper genomic and proteomic information is leading to pre-symptomatic diagnostic tests, safer medicines and a personalized healthcare paradigm in which patients receive treatments based on their unique complement of genes and proteins. Arrayit's 2015/2016 catalog showcases the new products and services, which are available worldwide through direct sales and a network of 60 international distributors. Arrayit customers include university and government laboratories, life sciences and biotechnology firms and the world's largest pharmaceutical companies.
"We have made a significant R&D investment to create innovative new genomics and proteomics products for the life sciences market," states Arrayit CEO Rene Schena. "The value-added, cost-effective solutions featured in our new catalog will drive company revenues and earnings beginning in the first quarter of this year."
About Arrayit Corporation
Arrayit utilizes its patented and proprietary microarray platform to lead and empower the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.
- Powerful Science for Life™
Visit www.arrayit.com or more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2013 and in Form 10-Q for the quarterly period ended September 30, 2014.
CONTACT: Investor Relations
Arrayit Corporation
408.744.1331
investorrelations@arrayit.com
Copyright © 2015 GlobeNewswire. All Rights Reserved
Arrayit Corporation Subsidiary Avant Diagnostics, Inc. Acquired by American Liberty Petroleum Corporation
Dec 31, 2014
Service
-
SUNNYVALE, Calif., Dec. 31, 2014 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTCQB:ARYC) announces that its subsidiary Avant Diagnostics, Inc., a medical technology company developing cutting edge medical diagnostic tests, has been acquired by American Liberty Petroleum Corporation (OTCBB:OREO). The board of directors and a majority of shareholders of American Liberty Petroleum Corporation have authorized a number of corporate actions in order to complete the acquisition, including a reverse split, a name change, authorization of Preferred Stock, and filing the required SEC disclosure statements. Upon the effectiveness of these corporate actions, Gregg Linn, Avant's CFO, will join the board of directors of the company as CEO and President.
In cooperation with Arrayit Corporation and DOCRO, Avant Diagnostics, Inc. is pursuing FDA approval of the market's first large panel biomarker monitoring and screening test for ovarian cancer. OvaDx® is an advanced microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA approval, Avant Diagnostics will offer OvaDx® as an elective test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer. OvaDx® will be used by doctors to advance the forefront of ovarian cancer treatment including improved surgical options, more effective chemotherapies, and to supplement existing tests including CA-125, OVA1®, and transvaginal ultrasound.
Safe Harbor
We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2014.
CONTACT: Investor Contact
Investor Relations
Arrayit Corporation
investorrelations@arrayit.com
Gregg Linn, CFO
Avant Diagnostics, Inc.
investors@avantdiagnostics.com
Copyright © 2014 GlobeNewswire. All Rights Reserved
OTC Markets Group Welcomes Arrayit to OTCQB
Dec 03, 2014
Service
New York, NY -
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced Arrayit Corporation (OTCQB: ARYC) is verified for trading on OTCQB®, the venture marketplace for entrepreneurial and development stage companies, effective December 3, 2014.
Arrayit leads professionals in the microarray industry by developing, manufacturing and marketing life science tools and integrated laboratory platforms for the analysis of genetic variation, biological function, and diagnostics. Arrayit provides its specialized equipment, tools, microarray manufacturing services to more than 10,000 research laboratories, pharmaceutical companies, academic institutions, clinical research organizations, government agencies and biotechnology companies around the globe.
U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX:OTCM) operates Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities. Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. We organize these securities into marketplaces to better inform investors of opportunities and risks – OTCQX®, The Best Marketplace; OTCQB®, The Venture Marketplace; and OTC Pink®, The Open Marketplace. Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors. To learn more about how we create better informed and more efficient financial marketplaces, visit www.otcmarkets.com.
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed
Media Contact:
Saskia Sidenfaden, OTC Markets Group Inc., +1 (212) 896-4428, saskia@otcmarkets.com
Copyright © 2014 OTC Markets. All Rights Reserved
(0)
(0)Scroll down for more posts ▼